drugset / Trial / NCT04962958
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Phase 2
Completed
30 enrolled
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Huashan Hospital · collabMeng Chao Hepatobiliary Hospital of Fujian Medical University · collabThe Second Affiliated Hospital of Harbin Medical University · collab
NaSingle-groupOpen-labelPrevention
Summary
This is an open-label，multi-center ，non-randomized ，single arm exploratory study . This clinical study is an investigator-initiated clinical trial（IIT ）. The objective of this study is to evaluate if the addition of hepatic artery infusion chemotherapy (HAIC) and Donafenib after curative resection for hepatocellular carcinoma patients with a solitary tumor≥5 cm and microvascular invasion （MVI） will prevent or delay the recurrence of the disease.
Timeline
- Start
- 2021-12-27
- Primary completion
- 2025-09-01
- Completion
- 2025-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | — | — |
| Subject | Leucovorin | Small molecule | — | Other |
| Subject | Oxaliplatin | Small molecule | — | Other |
| Subject | fluorouracil | Small molecule | — | Other |